Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8221 to 8235 of 9008 results

  1. Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545]

    Discontinued Reference number: GID-TAG444

    Technology appraisal guidance
    Discontinued

  2. Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517]

    Discontinued Reference number: GID-TAG436

    Technology appraisal guidance
    Discontinued

  3. Hernia

    Discontinued Reference number: GID-CGWAVE0771

    NICE guideline
    Discontinued

  4. Reducing the mortality and morbidity for healthcare associated infections

    Discontinued Reference number: GID-NG10059

    NICE guideline
    Discontinued

  5. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]

    In development Reference number: GID-TA11457 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

    Discontinued Reference number: GID-TA10637

    Technology appraisal guidance
    Discontinued

  7. Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

    Discontinued Reference number: GID-TA10722

    Technology appraisal guidance
    Discontinued

  8. Lenalidomide for untreated follicular lymphoma ID1245

    Discontinued Reference number: GID-TA10308

    Technology appraisal guidance
    Discontinued

  9. Mastocytosis (systemic) - masitinib [ID781]

    Discontinued Reference number: GID-TA10019

    Technology appraisal guidance
    Discontinued

  10. Blepharitis: antimicrobial prescribing

    Discontinued Reference number: GID-NG10168

    Antimicrobial prescribing guideline
    Discontinued

  11. Retifanlimab for treating anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]

    Discontinued Reference number: GID-TA10698

    Technology appraisal guidance
    Discontinued

  12. Renal cell carcinoma - sunitinib [ID1076]

    Discontinued Reference number: GID-TA10166

    Technology appraisal guidance
    Discontinued

  13. Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]

    Discontinued Reference number: GID-TA10574

    Technology appraisal guidance
    Discontinued

  14. Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

    Discontinued Reference number: GID-TA10464

    Technology appraisal guidance
    Discontinued

  15. Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

    Discontinued Reference number: GID-TA10484

    Technology appraisal guidance
    Discontinued